Tenaya Therapeutics, Inc. Common Stock Canaccord Genuity's 46th Annual Growth Conference

Yeah, great one. Thanks for having me, Whitney. I have been in the chair almost a month, so still new guy. When I thought about Tenaya and joining the company, really it is about the mission. We are looking for precision medicines for heart disease. We are modality agnostic, so we have gene therapy, we have small molecule, but really we are trying to address the underlying cause of the disease, and so the mission of the company really resonated with me. Also, the science, when I looked at the data presented to date, strong data, very encouraging. The team. The team that I met with during the interview process, very excited and energized to succeed in this space. We have a big year here, Q4, and we will get into this, but regulatory updates coming, our plans for advancing our small molecule TN-301.

Also we will talk about those in Q4, so a lot of near-term events for the company as well.

Right. As you said, with MYBPC3 in HCM, we are talking about about 120,000 patients in the U.S. here. That is about 20% of all HCM. Really what we see with these patients is a thickening of the left ventricle, so the heart is not able to pump blood where it needs to go in the body effectively. There is really a lack of effective treatments out there, especially with folks with more severe disease. We feel like targeting this area really our gene therapy can improve outcomes and results for these folks.

Sure. As I mentioned, these left ventricles thicken or they get large, so reducing the thickness of the left ventricle. LVMI is very important to us. We feel like that then would contribute to better outcomes. We are having discussions with regulators on appropriate endpoints, but the data we have shown to date has been very strong in that area, so we would think that would be appropriate.

Yeah. So in this cohort 2, it is the higher dose, so 6E13. Cohort 1 was half of that, and really well tolerated from a safety perspective. And again, the LVMI reductions we saw were very meaningful in the majority of patients. I think also what is important is from a feel and function kind of symptoms, those improved as well for most patients. So it is not just LVMI, but it is how these folks are feeling.

Right. Very well tolerated thus far. Favorable safety profile at both doses. We really have not seen, I think maybe what you are hinting at is some other folks in the space have seen some issues. We really have not seen that, so we are very confident that what we are moving forward is safe.